Recombinant Human Epidermal growth factor-like protein 7 (EGFL7)

Code CSB-YP890692HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP890692HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP890692HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP890692HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP890692HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
EGFL7
Uniprot No.
Alternative Names
EGF like domain 7; EGF like domain containing protein 7; EGF like domain multiple 7; EGF-like protein 7; EGFL 7; EGFL7; EGFL7_HUMAN; Epidermal growth factor like domain protein 7; Epidermal growth factor-like protein 7; MEGF 7; MEGF7; MGC111117; Multiple EGF like domain protein 7; Multiple EGF-like domains protein 7; Multiple epidermal growth factor like domain protein 7; Multiple epidermal growth factor-like domains protein 7; NEU1; NEU1 protein; NOTCH4 like protein; NOTCH4-like protein; RP11 251M1.2; UNQ187/PRO1449; Vascular endothelial statin; VE statin; VE-statin; ZNEU 1; ZNEU1
Species
Homo sapiens (Human)
Expression Region
24-273
Target Protein Sequence
YRPGRRV CAVRAHGDPV SESFVQRVYQ PFLTTCDGHR ACSTYRTIYR TAYRRSPGLA PARPRYACCP GWKRTSGLPG ACGAAICQPP CRNGGSCVQP GRCRCPAGWR GDTCQSDVDE CSARRGGCPQ RCVNTAGSYW CQCWEGHSLS ADGTLCVPKG GPPRVAPNPT GVDSAMKEEV QRLQSRVDLL EEKLQLVLAP LHSLASQALE HGLPDPGSLL VHSFQQLGRI DSLSEQISFL EEQLGSCSCK KDS
Protein Length
Full Length of Mature Protein
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
Gene References into Functions
  1. Data show that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was much higher than that of non-invasive GHPA. PMID: 29951953
  2. EGFL7 was found to be a potential predictor for HCC survival and metastasis state. PMID: 29970668
  3. Levels of both EGFL7 mRNA and EGFL7 protein are increased in blasts of patients with acute myeloid leukemia (AML) compared with normal bone marrow cells. High EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) and younger (age <60 y) patients with cytogenetically normal AML. PMID: 28533390
  4. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression PMID: 27611944
  5. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer PMID: 28275117
  6. Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line. PMID: 27725228
  7. Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines. PMID: 27650497
  8. Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone acetylation level PMID: 27259812
  9. These findings suggest that the stimulating effect of EGFL7-ESCs on fibroblast proliferation and migration may provide a useful strategy for wound healing. PMID: 27766530
  10. A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques PMID: 26799121
  11. By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis. PMID: 26722408
  12. The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase. PMID: 26542361
  13. EGFR mutational analysis is useful in the diagnosis of non-small-cell-lung cancer. PMID: 26288231
  14. The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer. PMID: 25592646
  15. EGFL7, OPN, and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma PMID: 25730089
  16. High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer. PMID: 25987088
  17. Loss of EGFL7 expression is associated with Malignant Pleural Mesothelioma. PMID: 26504055
  18. Data suggest that, in trophoblast cells, EGFL7 regulates cell migration and invasion/placentation by activating multiple signaling pathways via MAPK, PI3K (phosphatidylinositol 3-kinase), and NOTCH1 (translocation-associated notch protein 1). PMID: 25667199
  19. EGFL7 may predict response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer PMID: 25140000
  20. Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling. PMID: 25601205
  21. EGFL7 enhances EGFR-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PMID: 24945379
  22. demonstrate significantly reduced Egfl7 expression in pre-eclampsia placentas, concurrent with a downregulation of Notch target genes PMID: 24751645
  23. The loss of EGFL7 expression play a role in the development and progression of systemic sclerosis. PMID: 24286167
  24. egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries. PMID: 24595089
  25. EGFL7 promotes growth of Renal cell carcinoma by facilitating migration and tube formation of endothelial cells. These effects were produced by EGFL7-mediated focal adhesion kinase phosphorylation through combination with epidermal growth factor receptor. PMID: 24815445
  26. malignant glioma cells and glioma vascular endothelial cells highly express VE-statin/Egfl7, which is significantly correlated with the degree of malignancy. PMID: 24696719
  27. Egfl7 is significantly upregulated in human epithelial tumor tissues, suggesting Egfl7 to be a potential biomarker for human epithelial tumors, especially liver and breast cancer. PMID: 23558933
  28. study provides clinical data indicating a relationship between miRNA-126 and the clinical outcome of metastatic colorectal cancer patients treated with chemotherapy combined with anti-VEGF-A, whereas the impact of EGFL7 is more speculative PMID: 23922111
  29. Early-onset intrauterine growth restriction at 20-24 weeks' gestation is associated with higher values of EGFL7 expression in maternal plasma. PMID: 23280513
  30. Egfl7 expression is thus associated with better prognosis factors and with the absence of lymph node invasion in human breast cancer lesions. PMID: 23404186
  31. Data indicate that EGFL7 and integrin alphavbeta3 integrin colocalized in vesicular structures in uman umbilical vein endothelial cells (HUVECs). PMID: 23386126
  32. Two angiogenesis-associated transcripts (Egfl7 and Acvrl1) showed lower expression in early-onset PE versus late-onset pre-eclampsia and versus gestational age-matched controls. PMID: 22013081
  33. Human breast cancer lesions expressing high levels of Egfl7. PMID: 22037871
  34. Studies indicate that Egfl7 controls blood vessel development by promoting endothelial cell migration and proliferation. PMID: 22160377
  35. Heterogeneous methylation in the promoter region of EGFL7 was associated with cancer progression in non-small cell lung cancer. PMID: 22018271
  36. miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells. PMID: 20423846
  37. Studies indicate that two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. PMID: 20953557
  38. EGFL7 may be used as a predictive marker for glioma prognosis and as a potential therapeutic target for malignant glioma. PMID: 20213100
  39. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. PMID: 20837907
  40. miR-126 can inhibit proliferation of non-small cell lung cancer cells through one of its targets, EGFL7. PMID: 20034472
  41. is the first identified inhibitor of mural cell migration specifically produced by endothelial cells. PMID: 14592969
  42. Human EGFL7 may protect endothelial cell from hyperoxia-induced apoptosis by inhibition of mitochondria-dependent apoptosis pathway. PMID: 17934064
  43. Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. PMID: 18193184
  44. The lack of association between expression of miRNA and its host gene EGFL7 suggests their regulation by independent stimuli in colon cancer. PMID: 18521848
  45. Mature miR-126 can be generated from three different transcripts of EGFL7 with each one having its own promoter. PMID: 19116145
  46. Egfl7 promotes metastasis of hepatocellular carcinoma (HCC) by enhancing cell motility through EGFR-dependent FAK phosphorylation. PMID: 19824075

Show More

Hide All

Subcellular Location
Secreted, extracellular space.
Database Links

HGNC: 20594

OMIM: 608582

KEGG: hsa:51162

STRING: 9606.ENSP00000307843

UniGene: Hs.91481

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1